Pharmacokinetic and pharmacodynamic data to be derived from early-phase drug development: Designing informative human pharmacology studies

Clinical Pharmacokinetics

Volumn 47, Issue 6, 2008, Pages 373-381

  Cohen, Adam ^a  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

Author keywords

Clinical trial design; Data collection; Drug evaluation; Pharmacodynamics; Pharmacokinetics

Indexed keywords

DRUG;

ALGORITHM; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; MEDICAL INFORMATICS; METHODOLOGY; PHARMACODYNAMICS; PHARMACOKINETICS; PREDICTION; PRIORITY JOURNAL; REVIEW; SIMULATION;

CLINICAL TRIALS AS TOPIC; DRUGS, INVESTIGATIONAL; HUMANS; MODELS, BIOLOGICAL; RESEARCH DESIGN;

EID: 43649102392     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200847060-00002     Document Type: Review

References (41)

1. Zarafonetis CJ, Riley Jr PA, Willis III PW, et al. Clinically significant adverse effects in a phase 1 testing program. Clin Pharmacol Ther 1978; 24 (2): 127-32
2. Kenter MJ, Cohen AF. Establishing risk of human experimentation with drugs: lessons from TGN1412. Lancet 2006; 368 (9544): 1387-91
3. Steinbrook R. Protecting research subjects: the crisis at Johns Hopkins. N Engl J Med 2002; 346 (9): 716-20
4. Darragh A, Kenny M, Lambe R, et al. Sudden death of a volunteer. Lancet 1985; 1 (8420): 93-4
5. US FDA. International conference on harmonization; guidance on general considerations for clinical trials [online]. Fed Regist 1997 Dec 17; 62 (242): 66113-9. Available from URL: http://frwebgate.access.gpo.gov/cgi-bin/get-doc. cgi?dbname=1997_register&docid=fr17de97-92.pdf [Accessed 2008 Feb 16]
6. Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther 1997; 61 (3): 275-91
7. US FDA Center for Drug Evaluation and Research (CDER). Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers [online]. Rockville (MD): US FDA CDER, 2005 Jul 21. Available from URL: http://www.fda.gov/cder/guidance/index. htm#Pharmacology/Toxicology [Accessed 2008 Feb 16]
8. Peck CC, Cross JT. "Getting the dose right": facts, a blueprint, and encouragements. Clin Pharmacol Ther 2007; 82 (1): 12-4
9. Lalonde RL, Kowalski KG, Hutmacher MM, et al. Model-based drug development. Clin Pharmacol Ther 2007; 82 (1): 21-32
10. Expert Group on Phase One Clinical Trials. Final report [online]. Norwich: The Stationary Office, 2006 Dec 7. Available from URL: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH_063117 [Accessed 2008 Feb 16]
11. Cross J, Lee H, Westelinck A, et al. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999. Pharmacoepidemiol Drug Saf 2002; 11 (6): 439-46
12. de Visser SJ. A question based approach to drug development [PhD thesis]. Leiden: Leiden University, 2003
13. van Griensven JM, Jusko WJ, Lemkes HH, et al. Tolrestat pharmacokinetic and pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers and in patients with insulin-dependent diabetes. Clin Pharmacol Ther 1995; 58 (6): 631-40
14. Boot JD, de HS, Tarasevych S, et al. Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma. Am J Respir Crit Care Med 2007; 175 (5): 450-7
15. Hazekamp A, Ruhaak R, Zuurman L, et al. Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. J Pharm Sci 2006; 95 (6): 1308-17
16. Dumont GJ, de Visser SJ, Cohen AF, et al. Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects. Br J Clin Pharmacol 2005; 59 (5): 495-510
17. de Visser SJ, van der Post JP, de Waal PP, et al. Biomarkers for the effects of benzodiazepines in healthy volunteers. Br J Clin Pharmacol 2003; 55 (1): 39-50
18. de Visser SJ, van der PJ, Pieters MS, et al. Biomarkers for the effects of antipsychotic drugs in healthy volunteers. Br J Clin Pharmacol 2001; 51 (2): 119-32
19. Rijnbeek B, de Visser SJ, Franson KL, et al. REM sleep effects as a biomarker for the effects of antidepressants in healthy volunteers. J Psychopharmacol 2003; 17 (2): 196-203
20. van der PJ, de Waal PP, de Kam ML, et al. No evidence of the usefulness of eye blinking as a marker for central dopaminergic activity. J Psychopharmacol 2004; 18 (1): 109-14
21. van der PJ, Noordzij LA, de Kam ML, et al. Evaluation of tests of central nervous system performance after hypoxemia for a model for cognitive impairment. J Psychopharmacol 2002; 16 (4): 337-43
22. Aronson JK, Ferner RE. Joining the DoTS: new approach to classifying adverse drug reactions. BMJ 2003; 327 (7425): 1222-5
23. de Visser SJ, van der Post JP, Nanhekhan L, et al. Concentration-effect relationships of two rilmenidine single-dose infusion rates in hypertensive patients. Clin Pharmacol Ther 2002; 72 (4): 419-28
24. van der Post JP, de Visser SJ, Schoemaker RC, et al. Pharmacokinetic/ pharmacodynamic assessment of tolerance to central nervous system effects of a 3mg sustained release tablet of rilmenidine in hypertensive patients. J Psychopharmacol 2004; 18 (2): 221-7
25. Lesko LJ, Atkinson Jr AJ. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 2001; 41: 347-66
26. Rolan P, Atkinson Jr AJ, Lesko LJ. Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development. Clin Pharmacol Ther 2003; 73 (4): 284-91
27. US FDA. Innovation or stagnation: challenge and opportunity on the critical path to new medical products [online]. Rockville (MD): US FDA, 2004 Mar. Available from URL: http://www.fda.gov/oc/initiatives/criticalpath/ whitepaper.html [Accessed 2008 Feb 16]
28. van Gerven JM, Uchida E, Uchida N, et al. Pharmacodynamics and pharmacokinetics of a single oral dose of nitrazepam in healthy volunteers: an interethnic comparative study between Japanese and European volunteers. J Clin Pharmacol 1998; 38 (12): 1129-36
29. Wernevik LC, Nystrom P, Johnsson G, et al. Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran in young healthy Japanese men. Clin Pharmacokinet 2006; 45 (1): 77-84
30. de Visser SJ, Uchida N, van Vliet-Daskalopoulou E, et al. Pharmacokinetic differences between Caucasian and Japanese subjects after single and multiple doses of a potential combined oral contraceptive (Org 30659 and EE). Contraception 2003; 68 (3): 195-202
31. European Medicines Agency (EMEA). Note for guidance on statistical principles for clinical trials [document reference CPMP/ICH/363/96; online]. London: EMEA, 1998 Sep. Available from URL: http://www.emea.europa.eu/pdfs/ human/ich/036396en.pdf [Accessed 2008 Feb 16]
32. Dingemanse J, van Gerven JM, Schoemaker RC, et al. Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. Br J Clin Pharmacol 1997; 44 (5): 477-86
33. Van Gerven JMA, Roncari G, Schoemaker RC, et al. Integrated pharmacokinetics and pharmacodynamics of Ro 48-8684, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. Br J Clin Pharmacol 1997; 44 (5): 487-93
34. European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use. Guideline on the clinical investigation of the pharmacokinetics of therapeutic proteins [document reference CHMP/EWP/89249/2004; online]. London: EMEA, 2007 Jan 24. Available from URL: http://www.emea.europa.eu/pdfs/human/ewp/ 8924904enfin.pdf [Accessed 2008 Feb 16]
35. European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use. Points to consider on pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products [document reference CPMP/EWP/2655/99; online]. London: EMEA, 2000 Jul 27. Available from URL: http://www.emea.europa.eu/pdfs/human/ewp/265599en.pdf [Accessed 2008 Feb 16]
36. Franson KL, Burggraaf J, Bouman-Trio EA, et al. A phase I, single and fractionated, ascending dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietic mimetic antibody fusion protein, CNTO528, in healthy male subjects [abstract no. 4283; online]. Blood (ASH Annual Meeting Abstracts) 2005; 106 (11). Available from URL: http://abstracts.hematologylibrary.org/cgi/search?fulltext=franson&sendit= Enter&volume=106&issue=11&journalcode=ashmtg [Accessed 2008 May 13]
37. Lammertsma AA. Radioligand studies: imaging and quantitative analysis. Eur Neuropsychopharmacol 2002; 12 (6): 513-6
38. Promasys® clinical trial workflow and data management system [online]. Available from URL: http://www.promasys-software.com [Accessed 2008 Mar 5]
39. European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use. Guideline on requirement for first-in-man clinical trials for potential high-risk medicinal products [document reference EMEA/CHMP/SWP/28367/ 2007; online]. London: EMEA, 2000 Jun 3. Available from URL: http://www.emea.europa.eu/pdfs/human/swp/2836707en.pdf [Accessed 2008 Feb 16]
40. Bhattaram VA, Bonapace C, Chilukuri DM, et al. Impact of pharmacometric reviews on new drug approval and labeling decisions: a survey of 31 new drug applications submitted between 2005 and 2006. Clin Pharmacol Ther 2007; 81 (2): 213-21
41. Bhattaram VA, Booth BP, Ramchandani RP, et al. Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. AAPS J 2005; 7 (3): E503-12